Koordinierung und Durchführung der deutschen Beteiligung der WHO Studie Solidarity gemäß den WHO Protokollen

The aim of the project is to enable German clinics to participate in international clinical trials that are already testing known drugs for the treatment of COVID-19. These studies include, for example, the "Solidarity Trial of the WHO" or the comparable DisCOVery Trial under the leadership of the French Institute de la Santé et de la Recherche Médicale (INSERM). These studies are intended to test specific active substances in as many clinics and as many countries as possible on a large number of patients, for which there are first indications of effectiveness against COVID-19. These include, for example, an antiviral drug that was originally developed for Ebola, two malaria drugs, or combinations of drugs. The studies are flexible and are closely monitored internationally, so that unsuitable active substances are quickly discarded and new active substances are quickly included in the study. Overall, scientifically reliable results should be generated faster than usual. In addition, these studies can give as many patients as possible access to new, promising therapies.